Physiologically‐Based Pharmacokinetic Model‐Informed Drug Development for Fenebrutinib: Understanding Complex Drug‐Drug Interactions

Fenebrutinib is a CYP3A substrate and time‐dependent inhibitor, as well as a BCRP and OATP1B transporter inhibitor in vitro. Physiologically‐based pharmacokinetic (PBPK) modeling strategies with the ultimate goal of understanding complex drug‐drug interactions (DDIs) and proposing doses for untested...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yuan, Ma, Fang, Jones, Nicholas S., Yoshida, Kenta, Chiang, Po‐Chang, Durk, Matthew R., Wright, Matthew R., Jin, Jin Yan, Chinn, Leslie W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306618/
https://www.ncbi.nlm.nih.gov/pubmed/32383787
http://dx.doi.org/10.1002/psp4.12515

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306618/
https://www.ncbi.nlm.nih.gov/pubmed/32383787
http://dx.doi.org/10.1002/psp4.12515

Ejemplares similares